Chronic hepatitis B: Pathophysiology, diagnosis and treatment options

Frontiers of Gastrointestinal Research

Volumn 26, Issue , 2010, Pages 32-41

  Wursthorn, Karsten ^a   Mederacke, Ingmar ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ANTIVIRAL ACTIVITY; HEPATITIS B; HUMAN; IMMUNE DEFICIENCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 77949402339     PISSN: 03020665     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000258277     Document Type: Review

References (31)

1. Lee WM: Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
2. McMahon BJ: Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25:3-8.
3. Stevens CE, Beasley RP, Tsui J, et al: Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771-774.
4. McMahon BJ, Alward WL, Hall DB, et al: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151: 599-603.
5. Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(1 suppl):S6-S9.
6. Xunrong L, Yan AW, Liang R, et al: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: pathogenesis and management. Rev Med Virol 2001;11:287-299.
7. Wands JR, Chura CM, Roll FJ, et al: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975;68:105-112.
8. Samuel D, Muller R, Alexander G, et al: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
9. Cornberg M, Protzer U, Dollinger M, et al: Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007;45:1281-1328.
10. Ciesek S, Helfritz FA, Lehmann U, et al: Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis 2008;197:355-360.
11. Werle-Lapostolle B, Bowden S, Locarnini S, et al: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
12. Tang B, Kruger WD, Chen G, et al: Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004;72:35-40.
13. Chen CJ, Yang HI, Su J, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
14. Iloeje UH, Yang HI, Su J, et al: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
15. Bertoletti A, Ferrari C: Kinetics of the immune response during HBV and HCV infection. Hepatology 2003;38:4-13.
16. Guidotti LG, Rochford R, Chung J, et al: Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
17. Wieland S, Thimme R, Purcell RH, et al: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669-6674.
18. Thimme R, Wieland S, Steiger C, et al: CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
19. Chisari FV: Rous-Whipple Award Lecture: Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000;156:1117-1132.
20. Bertoletti A, Gehring AJ: The immune response during hepatitis B virus infection. J Gen Virol 2006; 87:1439-1449.
21. Rehermann B, Ferrari C, Pasquinelli C, et al: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-1108.
22. Lau GK, Piratvisuth T, Luo KX, et al: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
23. Dienstag JL, Schiff ER, Wright TL, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
24. Marcellin P, Chang TT, Lim SG, et al: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. Hepatology 2008;48:750-758.
25. Chang TT, Gish RG, de Man R, et al: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
26. Tenney DJ, Rose RE, Baldick CJ, et al: Two-year assessment of entecavir resistance in lamivudinerefractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-911.
27. Thio CL, Locarnini S: Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev 2007;9:40-53.
28. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-242.
29. Marcellin P, Heathcote EJ, Buti M, et al: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
30. van Bommel F, Wunsche T, Mauss S, et al: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425.
31. Hadziyannis SJ, Papatheodoridis GV: Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-141.